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Accepted 23 October 2019Background: Adipose tissue plays a crucial role in diet- and obesity-related insulin resistance, with implications
for several metabolic diseases. Identification of novel target genes and mechanisms that regulate adipocyte
function could lead to improved treatment strategies. RND3 (RhoE/Rho8), a Rho-related GTP-binding protein
that inhibits Rho kinase (ROCK) signaling, has been linked to diverse diseases such as apoptotic cardiomyopathy,
heart failure, cancer and type 2 diabetes, in part by regulating cytoskeleton dynamics and insulin-mediated
glucose uptake.
Results:We here investigated the expression of RND3 in adipose tissue in human obesity, and discovered a role
for RND3 in regulating adipocyte metabolism. In cross-sectional and prospective studies, we observed 5-fold
increased adipocyte levels of RND3 mRNA in obesity, reduced levels after surgery-induced weight loss, and
positive correlations of RND3 mRNA with adipocyte size and surrogate measures of insulin resistance
(HOMA2-IR and circulating triglyceride/high-density lipoprotein cholesterol (TAG/HDL-C) ratio). By screening
for RND3-dependent gene expression following siRNA-mediated RND3 knockdown in differentiating human
adipocytes, we found downregulation of inflammatory genes and upregulation of genes related to adipocyte
ipolysis and insulin signaling. Treatment of adipocytes with tumor necrosis factor alpha (TNFα), lipopolysaccha-
ride (LPS), hypoxia or cAMP analogs increased RND3 mRNA levels 1.5–2-fold. Functional assays in primary
human adipocytes confirmed that RND3 knockdown reduces cAMP- and isoproterenol-induced lipolysis,
which were mimicked by treating cells with ROCK inhibitor. This effect could partly be explained by reduced
protein expression of adipose triglyceride lipase (ATGL) and phosphorylated hormone-sensitive lipase (HSL).
Conclusion:Wehere uncovered a novel differential expression of adipose RND3 in obesity and insulin resistance,
which may at least partly depend on a causal effect of RND3 on adipocyte lipolysis.
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. This is an open access article undermay largely distinguish people with metabolically “unhealthy” and
“healthy” obesity [4]. Increased adipose tissue inflammation further as-
sociates with elevated circulating free fatty acids (FFA), visceral and ec-
topic lipid accumulation and lipotoxicity, likely in large part due to
increased adipocyte lipolysis [5–8]. Identification of novel genes and
pathways that mediate altered adipose tissue function in obesity is
therefore of great interest, and may enable development of new thera-
peutic strategies.
Lipolysis in adipocytes is critical for lipid handling and systemicmet-
abolic homeostasis [9]. Adipocyte lipolysis increases during fasting,
exercise and other factors to release FFA for use by other tissues and
organs, in part induced by beta-adrenergic stimuli. These stimuli induce
the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)
pathway, and consequently activate lipolytic enzymes, most notably
hormone-sensitive lipase (HSL) by phosphorylating activity-the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mouse and ser660 in rat) [10–12]. Additional pathways also stimulate
lipolysis via HSL and/or other enzymes [13], such as activation of
adipose triglyceride lipase (ATGL) by 5′ adenosine monophosphate-
activated protein kinase (AMPK) [14]. Feeding and increased insulin
levels inhibit these processes in a normal physiologic regulation [9].
However, while short-term overfeeding (for a few days) does not pro-
voke dysregulated lipolysis in adipocytes [15], conditions of chronic
nutrient stress over weeks and months may increase lipolysis in con-
junction with developing insulin resistance in adipocytes. Hence, a
partial reduction in lipolysis may enhance glucose metabolism [6].
Genetic evidence and different experimental models further support
that genotype-dependent increases in lipolysis may cause insulin resis-
tance and metabolic diseases by promoting visceral and ectopic fat
accumulation [7,16], although de novo lipogenesis and impaired lipid
handling in adipocytes may also contribute [17].
RND3 (Rho-related GTP-binding protein RhoE/Rho8) is amember of
the Rnd family, which represents a sub-group of the Rho family of small
GTP-binding proteins (G-proteins). The Rnd family also includes Rnd1
(Rho6) and Rnd2 (Rho7) [18]. Most small G-proteins are molecular
switches, which cycle between a non-active, resting GDP-bound form
and an active.
GTP-bound form [18]. However, unlike RND1 and RND2, RND3 with
its unique structure [19] has no intrinsic GTPase activity and is insensi-
tive to the Rho-specific GTPase-activating proteins (GAPs) [20].
Through its basic function in regulating the formation of actin stress
fibers and cytoskeleton dynamics, RND3 has been implicated as a
driving factor in the pathophysiology of diseases such as apoptotic
cardiomyopathy, heart failure, and cancer [21]. RND3 acts in part by
inhibiting the activity of RhoA and its downstream effector
Rho-associated coiled-coil containing kinase 1 (ROCK1), signals that
induce stress fiber formation [22]. RND3 was previously shown to
impair insulin-mediated glucose uptake in skeletal muscle of patients
with obesity and T2D through direct binding and inhibition of ROCK1
[23]. Furthermore, in gastric cancer cells, hypoxia-inducible factor-1α
(HIF-1α), a transcription factor implicated in adipose tissue insulin
resistance and inflammation [24,25], was found to bind a hypoxia-
responsive element (HRE) in the RND3 promoter to induce RND3
expression [26]. These data point to a possible role for RND3 in regulat-
ing adipose tissue function. We here hypothesized that RND3 regulates
adipose tissue metabolism and function in humans, with a possible role
in obesity and insulin resistance.
2. Methods
2.1. Ethics and Subjects
The study was approved by the Regional Ethics Committee (REK
Vest, Norway, approval numbers 2010/512 and 2010/3405, and theTable 1
Overview of cohorts and clinical data.
M/F Age (years) BMI (kg/
Cohort 1
Lean 7/6 44.0 ± 17.5 23.0 ± 2
Obese 4/12 39.4 ± 10.9 53.3 ± 4
Post-surgery 4/12 40.3 ± 10.9 33.1 ± 5
Cohort 2
Lean 5/7 43.5 ± 11.6 22.8 ± 2
Obese 4/8 43.2 ± 9.98 43.7 ± 5
Post-surgery 1/5 43.8 ± 9.13 32.9 ± 5
Cohort 3
Non-obese/obese 0/56 42.9 ± 12.0 33.1 ± 9
M/F, male/female; BMI, body-mass index (kg/m2); OM, omental adipose tissue; Pre, before baria
IR, homeostatic model assessment 2 of insulin resistance; TAG, triacylglycerol; HDL, high-dens
a n = 6 due to missing data.Regional Committee of Ethics in Stockholm, Sweden). Each subject
gave written informed consent. Blood and adipose tissue biopsies
were collected from three cohorts (Cohorts 1–3, Table 1).
2.2. Adipose Tissue Sampling
Human adipose tissuewas analyzed for three different cohorts. Sub-
cutaneous (SC) and omental (OM) adipose tissue biopsies were
obtained by surgical excision from patients with severe obesity under-
going bariatric surgery in Western Norway (Førde Hospital and Voss
Hospital), as previously described [27,28] (Cohorts 1–2, Table 1).
Subcutaneous biopsies were also obtained from a subset of patients
one year after bariatric surgery and from non-obese healthy people
(Cohort 1) [27]. In Cohort 2 [28], adipocytes and the stromal vascular
fraction (SVF) were isolated from SC adipose tissue. In Cohort 3 [29],
subcutaneous adipose tissue samples were collected by needle biopsy
from the periumbilical region of non-obese (n = 26) and obese (n =
30) women. Clinical details of Cohort 3 as well as sample preparation
and gene microarrays are described in the original publication [29].
The samples were collected between 2003 and 2010.
2.3. Adipose Tissue Homogenization and Fractionation
Frozenwhole tissue (200-300mg)was homogenized in a 2mL safe-
lock eppendorf tubewith 1mLQiazol lysing buffer (Qiagen) and a 5mm
metal bead (Millipore), using a TissueLyser (Qiagen) with three re-
peated shakings at 25 Hz for 2 min each. To isolate adipocytes and
SVF, 700–800 mg of adipose tissue was treated with collagenase and
thermolysin (Liberase Blendzyme 3, Roche), and completed within 1 h
±5 min, as previously described [30]. The tissue/cells were frozen
immediately and stored at−80°C for later gene expression analysis.
2.4. Adipocyte Cultures
Primary human adipose stromal cells (hASCs) were isolated from
subcutaneous liposuction aspirate, cultured and differentiated, as de-
scribed previously [30]. 3T3-L1 cells were cultured in 24-wells plates
in DMEM 4.5 g/L glucose containing 1% penicillin and streptomycin
(PEST), at 37°C, as described previously [31]. For the hypoxia experi-
ment, the adipocytes were placed in an incubator with an atmosphere
of 2% oxygen, 5% CO2 and 93% N2, to be compared with the standard
atmosphere (5% CO2, 21% oxygen and 74% N2). Human preadipocytes
from the human SGBS adipocyte cell line [32] were cultured and propa-
gated in proliferation medium consisting of DMEM-Ham's F-12 (1:1)
supplemented with 10% fetal calf serum (FCS), 33 μM biotin, 20 μM
DL-pantothenate, 100 U/mL penicillin and 100 μg/ml streptomycin. Dif-
ferentiationwas inducedwithDMEM/F12mediumcontaining 10 μg/mL
transferrin, 66 nM insulin, 1 nM triiodothyronine (T3) and 100 nM
cortisol. During the first 4 days of differentiation, the medium was alsom2) HOMA2-IR TAG/HDL Figure
.5 1.45 ± 0.63a 0.83 ± 0.45 1B
.3 3.0 ± 1.65 1.48 ± 0.74
.0 1.63 ± 0.64 1.50 ± 1.18
.1 1.11 ± 0.40 0.96 ± 0.67 1C-D, 2A
.2 2.38 ± 1.00 2.36 ± 1.09
.7 1.32 ± 0.38 0.95 ± 0.36
.9 1.38 ± 1.15 N/A 2B
tric surgery; Post-surgery, one year after bariatric surgery/after profound fat loss; HOMA2-
ity lipoprotein cholesterol.
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methasone and 2 μM rosiglitazone. For some experiments, cells were
treated with the cAMP analogs 8CPT-cAMP or dibutyryl cAMP
(dcAMP) (activators of PKA as well as Exchange protein activated by
cAMP (Epac) signaling), 6 MB-cAMP (activator of PKA signaling), iso-
proterenol (β3-adrenergic receptor agonist) or ROCK inhibitor
(Y27632, selective inhibitor of p160ROCK).
2.5. siRNA Transfection
After differentiation for up to 11 days, hASCs were transfected for
48-72 h with 25 nM ON-TARGETplus human siRNA SMARTpool
(Dharmacon, Thermo Fisher Scientific) using HiPerFect (Qiagen) (non-
targeting siRNA control and siRNA against RND3 (L-007794-00-0005)
or HIF1A (J-004018-07). Cells were collected in buffer RLT (Qiagen)
and stored at−80°C until RNA extraction.
For the lipolysis assay (see below), hASCs were transfected at day 8
of differentiation with siRNAs targeting RND3 or a scramble non-
targeting siRNA pool using Neon electroporator (Invitrogen) according
to the manufacturer's protocol. Briefly, for one transfection reaction 1
million of hASCs suspended in 90 μL of R buffer were mixed with
200 pmol/μL of siRNA and transfection was performed using a 100 μL
electroporation tip. Electroporation conditions were 1400 Volts, 20 ms
width, and 2 pulses. Following electroporation the cells were plated in
48-well plates at a density of 55.000 cells/well in 250 μL medium, with
a final siRNA concentration of 40 nM. The next day medium was re-
placed to the fresh medium with reduced insulin (0.01 nM), and
ROCK inhibitor was added at a final concentration of 10 μM, followed
by incubation of the cells for 72 h. Each samplewas prepared in quadru-
plicates and the experiment was repeated three times.
2.6. RNA Extraction
The RNeasy Lipid TissueMidi Kit (whole tissue) orMini Kit (Qiagen)
was used to extract total RNA. NanoDrop spectrophotometer and
Agilent 2100 Bioanalyzer were used to measure amount (ng/μL) and
quality (RNA integrity number) of RNA.
2.7. qPCR Analysis
cDNA was prepared from 1 μg total RNA by the Transcriptor First
Strand cDNA Synthesis Kit (Roche), and diluted 1:10 with PCR-grade
water. For the cell fractions and cell culture, the SuperScript® VILO™
cDNA Synthesis Kit (Invitrogen) was used, with an input of 100 ng
(cell fractions) and 500 ng (cell culture) total RNA per sample, followed
by 1:20 dilution with PCR-grade water. The LightCycler480 Probes
Master kit and the LightCycler480 rapid thermal cycler system (Roche
Applied Science) were used to perform qPCR. Target and reference
genes were amplified by specific primers and Universal ProbeLibrary
(UPL) probes (Roche) (Table 2). Amplification efficiency based onTable 2







Rplp0 Mousestandard curves was used to calculate mRNA concentrations. TBP and
IPO8 [33] were chosen as reference genes based on their stable expres-
sion in biopsies and primary culture, respectively, and because they
showed similar expression levels as the target genes.
2.8. Microarray Analysis
The Illumina microarray analyses were performed as described pre-
viously [27]. Briefly, 300ng of total RNA from each samplewas reversely
transcribed, amplified and Biotin-16-UTP–labeled. NanoDrop spectro-
photometer and Agilent 2100 Bioanalyzer were used to measure
amount (15–52 mg) and quality of the labeled cRNA. 750 ng of biotin-
labeled cRNA was hybridized to the HumanRef-8v.3 (whole tissue) or
HumanHT-12v.3 Illumina Sentrix BeadChip according tomanufacturer's
instructions. The Affymetrix microarray data from Cohort 3 were
analyzed as described in detail previously [29].
2.9. RNA Sequencing
cDNA libraries were generated via the TruSeq Stranded mRNA
Library Prep kit. RNA-seq was then performed at the Illumina Hiseq
4000 platform at the Genomics Core Facility, Bergen. Aligned
reads were put into featureCounts (Version 1.5.2) with options
“featureCounts -T 64 -p -t exon -g gene_id”, resulting in a matrix of
raw counts. Data were normalized and differential expression analysis
was performed with DESeq2 (Version 1.22.2). For pathway enrichment
analysis we used the KEGG database. Significant ontologieswere visual-
ized using ggplot2 package (Version 3.1.0). PCA plots were generated
using the R package ‘DESeq2’ (Version 1.22.2) and the Volcano plot of
the differential expression analysis by the R package ‘Enhanced Volcano’
(Version: 1.0.1).
2.10. Lipolysis in In Vitro Differentiated Adipocytes
Glycerol in conditioned media was measured using Free Glycerol
Reagent (Sigma Aldrich) and Amplex UltraRed (Invitrogen) according
to the manufacturer's instructions. Amplex Ultra Red was diluted 100-
fold in Free Glycerol Reagent, mixed with 20 μL of conditioned medium
in a 96-well plate, incubated at room temperature for 15 min, and
fluorescence was measured (excitation/emission 530/590) using an
Infinite M200 plate reader (Tecan Group, Männedorf, Switzerland).
The cells were lyzed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA) and protein
concentrationwas assessed using BCA Protein Assay Kit (Thermo Fisher
Scientific). Glycerol valueswere normalized to the proteins in eachwell.
2.11. SDS-PAGE and Immunoblotting
Fully differentiated SGBS cells (day 15)were transfectedwith 25 nM
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protein samples were prepared in RIPA buffer with phosphatase
(phosSTOP; Roche) and protease inhibitors (cOmplete; Roche). After
centrifugation (20,000 g, 4°C, 15 min), the fatty supernatant was
removed, and protein concentrations were assessed by Pierce™ BCA
Protein Assay kit (Thermo Fisher Scientific). Denatured protein samples
were analyzed by SDS-PAGE and immunoblotting using mouse anti-
RND3 (1:500, Cell Signaling#3664), rabbit anti-HSL (1:750, Cell
Signaling#4107), rabbit anti phosphorylated (p) HSLser660 (human
ser650) (1:750, Cell Signaling#4126) or rabbit anti-ATGL (1:750, Cell
Signaling#2138) antibodies.
2.12. Statistics
P-values were calculated by ANOVA and Tukey's posthoc test or t-
test, as indicated. Correlations were calculated by Pearson's correlation.
These statistics were performed in Excel for Windows 10. For the
Illumina microarray analyses we used Significance Analysis of Microar-
rays (SAM) to identify differentially expressed genes, as described
previously [27]. Details on the statistical analysis of the Affymetrix
microarrays in Cohort 3 are described in [29]. For the RNA sequencing,
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Fig. 1. Elevated adipose RND3 mRNA expression in obesity. A. Lean and obese (ob/ob) B6 an
hypothalamus, soleus, gastrocnemius and pancreatic islets were collected (n = 5). Data are
adipose transcriptome dataset (Illumina BeadChips, Cohort 1). Data are presented as mean ±
n = 16, omental obese n = 12). C. Adipocytes and stromal vascular fraction (SVF) were isol
were extracted from a microarray transcriptome dataset (Illumina BeadChips). Data are prese
isolated from subcutaneous adipose tissue also after profound fat loss (one year after baria
gene). Data are presented as mean± SD (n= 6). P-values were calculated by one-way ANOVA
BTBR, Black and Tan BRachyury mouse strain; Ob, obese; Ob/ob, obese leptin-deficient; OM, om
subcutaneous adipose tissue; SVF, stromal vascular fraction. * p b .05; ** p b .01; *** p b .001.(false discovery rate (FDR) cutoff b0.1) were used as an input and
Fischer's exact test was used to identify statistically over/under repre-
sented pathways (FDR cutoff b0.05).
3. Results
3.1. Up-regulation of RND3 in Obesity and Metabolic Syndrome
To examine the expression of RND3 in adipose tissue, we first ana-
lyzed publically available transcriptome data for two strains of mice
with genetically induced obesity due to leptin deficiency (ob/ob),
i.e., obesity-prone C57BL/6 (B6) and the insulin resistant-prone Black
and Tan BRachyury (BTBR) [34]. In comparison to other metabolic
tissues, adipose tissue showed the highest Rnd3mRNA expression and
increased levels in the obese and insulin resistant mice compared to
controls after 4 weeks of feeding, and also after 10 weeks in the BTBR
model (Fig. 1A). The increased expression already at 4 weeks of
overfeeding in the BTBR model is consistent with a primary effect of
Rnd3 on insulin resistance and consequent diabetes, since these mice
are insulin resistant at all ages independent of obesity but develop
severe diabetes first after 10 weeks [34]. Although showing the lowest
expression, pancreatic islets expressed significantly less Rnd3 in bothtes SVF































4 1010 4 10 4 10 4 104 10 4 10
d BTBR mice were fed for 4 or 10 weeks (ab libitum). Adipose tissue (epididymal), liver,
presented as mean ± SD. B. mRNA signal intensities were extracted from a microarray
SD (lean n = 13, subcutaneous adipose tissue obese n = 16, subcutaneous post-surgery
ated by digesting fresh human adipose tissue with collagenase. mRNA signal intensities
nted as mean ± SD (n = 12 per group). D. For a subset of the patients, adipocytes were
tric surgery). RND3 mRNA was measured by qPCR and related to TBP mRNA (reference
and Tukey's posthoc test, except panel D (paired t-test). B6, C57BL/6 inbredmouse strain;
ental adipose tissue; Pre, before bariatric surgery; Post, one year after bariatric surgery; SC,
5S.N. Dankel et al. / Metabolism Clinical and Experimental 101 (2019) 153999strains at 4 weeks. On the other hand, muscle (gastrocnemius) showed
opposite effects in the two strains after 10 weeks (Fig. 1A).
We further compared RND3mRNA expression in whole adipose tis-
sue biopsies from13 lean and 16 extremely obese insulin resistant or di-
abetic Caucasians (Cohort 1, Table 1) [27]. Relative to lean samples,
obese samples showed a 6-fold increase in RND3 mRNA in abdominal
subcutaneous fat, and a return to normal levels after profound fat loss
due to bariatric surgery (average BMI of 33 one year after surgery)
(Fig. 1B). RND3 also showed a notable expression in omental adipose
tissue from the same extremely obese patients, around 35% lower
than in subcutaneous fat (Fig. 1B). In comparison, adipose expression
levels of RND1 and RND2 were around 10-fold lower than those of
RND3, and showed no alterations in obesity (Fig. S1A).
Because adipose tissue harbors a heterogeneous population of cells,
including adipocytes, progenitor cells and immune cells, we measured
RND3 mRNA expression separately in adipocytes and stromal vascular
fraction (SVF) isolated directly from subcutaneous (lean and obese)
and omental (obese) adipose tissue (n = 12 in the lean and obese
groups, Cohort 2, Table 1). RND3 mRNA was expressed ~2-fold higher
in isolated adipocytes from obese compared to lean samples, while we
observed no such obesity-dependent expression in SVF (Fig. 1C).
Consistent with the whole tissue data, omental adipocytes and SVF
from the obese patients showed 40–60% lower RND3 expression than
subcutaneous adipocytes collected from the same patients (Fig. 1C).
We also measured changes in RND3 mRNA in isolated subcutaneous
adipocytes collected from a subset of these patients before and after
profound fat loss, and found that adipocyte RND3 mRNA was halved
(Fig. 1D), completely reversing the 2-fold higher level seen in obesity
relative to lean patients (Fig. 1C).
We further examined whether RND3 expression in isolated adipo-
cytes might relate to whole-body insulin sensitivity and circulating
lipids. We first correlated subcutaneous RND3 mRNA across the lean
and obese patients with HOMA2-IR and TAG/HDL ratio. Whereas SVF
expression of RND3mRNA showed no correlations with these surrogate
measures of insulin resistance (not shown), adipocyte RND3 mRNA
showed a strong positive correlation with both HOMA2-IR and TAG/Fig. 2. Adipose RND3 mRNA correlates with insulin resistance and adipocyte size. A. RND3 m
adipocytes and correlated with HOMA2-IR and TAG/HDL ratio (Cohort 2). B. RND3mRNA was
BMI, HOMA2-IR and adipocyte number and size (Cohort 3). The Pearson correlation coefficie
body-mass index; HDL, high-density lipoprotein cholesterol; HOMA2-IR, homeostatic model aHDL ratio (Fig. 2A). We observed a similar pattern in isolated omental
adipocytes (Fig. 2A). Another cohort of 56 Caucasians (Cohort 3,
Table 1) confirmed significant positive correlations for RND3 mRNA in
subcutaneous whole tissue with BMI and HOMA2-IR (r = 0.33, p =
.012) (Fig. 2B), as well as with waist-to-hip ratio (WHR) (r = 0.29, p
= .034) (not shown). Moreover, consistent with the relationship of ad-
ipose RND3 with phenotypes related to insulin resistance, RND3 corre-
lated inversely with plasma glucose disappearance rate (KITT based
on an insulin tolerance test) (r = −0.39, p = .027) (not shown).
To assess whether adipose RND3 might contribute to these
metabolic phenotypes via adipocytes, we correlated RND3 mRNA with
subcutaneous adipocyte morphology (number and size). While RND3
showed no significant correlation with adipocyte number, we observed
a strong positive correlation with subcutaneous adipocyte volume (r=
0.47, p = .0002) (Fig. 2B), and with hypertrophic fat cell morphology
defined by the morphology value, i.e. the relative level of adipocyte hy-
pertrophy or hyperplasia at any given body fat mass [35] (r= 0.3, p =
.02). By multiple regression analysis we found that the positive
association with adipocyte size remained significant after correcting
for BMI (β = 0.19, p = .047), despite a strong correlation between
RND3 andBMI (β=0.67, p b .0001). Noneof the other variables showed
a significant correlation with RND3mRNA after BMI adjustment.
3.2. Adipose RND3 is Co-expressed with Pro-inflammatory Genes
The strong relationship between RND3 expression and obesity-
related metabolic features prompted us to explore functional roles of
RND3 in adipose tissue. To this end, we first performed co-expression
analyses to predict cellular processes associated with altered RND3
expression in vivo, for subcutaneous and omental whole adipose tissue
(Cohort 1) and isolated adipocytes (Cohort 2) from patients with
morbid obesity. Genes positively co-expressed with RND3 consistently
showed a significant enrichment in cellular pathways related to infec-
tion/inflammation and insulin signaling/resistance (Fig. 3A). The
infection-related pathways essentially represented inflammatory
genes, such as IL6, TNFRSF1A, and NFKB. IL17 signaling has recentlyRNA was measured by microarrays (Illumina BeadChips) in subcutaneous and omental
measured in subcutaneous adipose tissue by Affymetrix microarrays and correlated with
nt and p-value are shown. Clinical data were missing for some patients in Cohort 2. BMI,












































































































Fig. 3. Genome-wide co-expression analysis links RND3 to inflammation and insulin resistance pathways in adipocytes. A. RND3mRNA levels in isolated subcutaneous adipocytes (Cohort
2) and subcutaneous or omental whole adipose tissue (Cohort 1) was correlated with other transcript levels globally (Illumina microarray analysis, log2-transformed signal intensities).
Genes positively co-expressedwith RND3 (Pearson's r ≥ 0.7)were subjected to KEGGpathway analysis (no significantKEGGpathwayswere retrieved for genes anti-expressedwith RND3).
Pathwayswith significantRND3-correlated gene enrichment in at least two of the three datasets are shown, sorted by enrichment in isolated adipocytes. For panels B-D,RND3/Rnd3mRNA
levels weremeasured by qPCR, calculated relative to IPO8 (human) or Rplp0 (mouse), and normalized to the median value of the control triplicate in each experiment. B. Primary human
adipose stromal cells (hASCs) were cultured in 24-well plates and differentiated for 3 days before stimulation with LPS (1 μg/ml) or TNFα (10 ng/ml). The data are presented as mean ±
SEM for two combined experiments on adipose cells from individual subjects performed in triplicates (n=6). C. 3 T3-L1 adipocyteswere differentiated in vitro for 8 days and incubated at
an atmospherewith 20% or 2% oxygen for 24h. The data are presented asmean±SD (n=3). D. Primary hASCswere differentiated for 11 days before transfectionwith non-targeting (NT)
siRNA or siRNA against HIF1A (25 nM siRNA). Cells were harvested 72 h later (day 14). The data are presented as mean ± SEM (n = 3). OM, omental; SC, subcutaneous; siRNA, small
interfering RNA. * p b .05; ** p b .01.
6 S.N. Dankel et al. / Metabolism Clinical and Experimental 101 (2019) 153999been implicated in chronic inflammation in adipose tissue [36], in part
dependent on signals from adipocytes [37]. The cytosolic DNA-sensing
pathway also relates to inflammation, involving conversion of GTP and
ATP to cyclic GMP-AMP (cGAMP) via cGAMP synthase (cGAS) which
promotes cellular senescence via interferon signaling and inflammatory
gene expression [38]. The co-expression analyses also indicated a link to
HIF-1 signaling, which mediates effects of adipocyte oxygen consump-
tion on inflammation and insulin resistance [39]. No significant enrich-
ment was seen for the isolated omental adipocytes, nor for RND3 anti-
expressed genes regardless of sample type.
The co-expression with inflammation-related genes raised the
possibility that a pro-inflammatory milieu in adipose tissue may
contribute to increased RND3 expression in obesity. To test this, we
treated developing primary human adipocytes with the endotoxin lipo-
polysaccharide (LPS) or the cytokine tumor necrosis factor (TNF)-alpha,
and found that these pro-inflammatory stimuli increased RND3 mRNA
1.5-fold (Fig. 3B). Similarly, consistent with the co-expression of RND3with the HIF-1 signaling pathway, exposure of 3 T3-L1 adipocytes to
hypoxia (2% O2) increased Rnd3 mRNA 2-fold (Fig. 3C). Conversely, in
differentiating primary human adipocytes, knockdown of HIF1A caused
a 30% reduction inRND3 expression (Fig. 3D). These data are in linewith
the previously reported HIF-1α-mediated transactivation of RND3 in
gastric cancer cells [26].
3.3. RND3 Knockdown Affects Metabolic and Inflammatory Genes
So far the presented data are correlative in terms of downstream
functions of RND3 in adipose tissue. To establish causality, we differen-
tiated primary human adipocytes in vitro (Fig. 4A) and performed RNA
sequencing with and without siRNA-mediated knockdown of RND3.
Based on the expression profile of PPARG2, a master regulator of
adipogenesis and adipocyte function, we performed the knockdown
on day 6–8 of differentiation coinciding with peak PPARG2 levels on
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Fig. 4. Expression of RND3mRNA during adipogenic differentiation of primary human adipose stromal cells (hASCs). The cells were induced to differentiate by supplementing the culture
mediumwith cortisol (100 nM/L), insulin (66 nM/L), transferrin (10 μg/mL), biotin (33 μM/L), pantothenate (17 μM/L), T3 (1 nM/L) and rosiglitazone (10 μM/L), changingmedium every
2–3 days. Rosiglitazone (10 μM) was added during the first six days. A. RND3 and PPARG2mRNA expression was calculated relative to IPO8 for differentiated cells and undifferentiated
controls for each time-point. Data are presented asmean± SD for independent experiments from 4 people. B. The increase in lipid accumulation as observed under themicroscope (40×).
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progenitors and mature adipocytes (qPCR Ct values around 25–26)
(Fig. 4B). For primary adipocyte cultures obtained from 6 women
(BMI 28.6 ± 2.4 kg/m2, age 39.5 ± 12.6 years), principal component
analysis (PCA) of the RNA sequencing data showed a clear separation
of samples treated with non-targeting or RND3-targeting siRNA
(Fig. 5A). A volcano plot showed that RND3 was, except for DDAH1,
the most significant differentially expressed gene in cells with RND3
knockdown, and revealed a tendency of greater overall downregulation
than upregulation (Fig. 5B). Although the 6 experiments showed a
notable individual variation (Fig. 5C), paired analysis of controls
compared to knockdown for each individual retrieved a total of 134
downregulated and 92 upregulated genes within a false discovery rate
(FDR) b 0.1 cutoff (Table S1).
Pathway analysis for these transcripts showed an enrichment of up-
regulated genes in adipocyte lipolysis, AMPK signaling and insulin sig-
naling, and of downregulated genes in pro-inflammatory pathways
reminiscent of the in vivo co-expression analysis (Fig. 5D). Among the
genes involved in lipolysis were ADCY1, IRS2, LIPE and SCD, which
were also linked to insulin-mediated suppression of lipolysis and
AMPK signaling (Fig. 5E). Additional genes related to insulin signaling
included FASN, ACACB and PCK1 associated with lipid storage
(e.g., PCK1 (PEPCK) controls adipocyte glyceroneogenesis to promote
intracellular esterification of FFA to glycerol [40]).
3.4. ROCK Expression Associates with Adipocyte Metabolism and Obesity
Given the role of Rho kinase (ROCK) in mediating cellular effects of
RND3, with important metabolic roles in skeletal muscle [23] and
adipose tissue [41,42], we further reanalyzed a published global gene
expression dataset for a mouse dedifferentiated fat (DFAT) cell line
treated for 4 days with and without ROCK inhibitor [43]. Significantly
enriched pathways in the ROCK-inhibitor treated cells were regulation
of lipolysis in adipocytes and glycerolipid metabolism (i.e., glyceride/
FFA cycling [44]), along with PPAR signaling (all for upregulated
genes; no enrichment was seen for downregulated genes) (Fig. 6A).
The increased expression of genes in these pathways coincided with a
stimulatory effect of the ROCK inhibitor on adipogenic redifferentiation
in the DFAT cells [43].
Metabolic effects of the ROCK inhibitor could depend on ROCK iso-
form expression. To assess the relevance of the respective isoforms in
adipose and other tissues, we examined Rock1 and Rock2mRNA expres-
sion levels and their changes in metabolic tissues during diet-induced
obesity and insulin resistance. Rock1 showed the highest expression in
pancreatic islets, adipose tissue and liver, and Rock2 in muscle and adi-
pose tissue (Fig. 6B). However, only adipose tissue showed significantincreases in Rock1 as well as Rock2mRNA in the obese ob/ob B6 and in-
sulin resistant BTRB mice, particularly after 4 weeks of feeding. On the
other hand, liver and muscle showed significant reductions in Rock1
mRNA, and no changes in Rock2 mRNA (Fig. 6B).
3.5. RND3 Regulates Adipocyte Lipolysis
The effect of RND3 knockdown on genes involved in adipocyte lipol-
ysis prompted us to measure glycerol release as a direct measure of li-
polysis. Lipolysis can be induced through increased levels of beta-
adrenergic receptor activation and cAMP, with consequent activation
of PKA which phosphorylates specific residues on HSL [12,13]. When
treating developing primary human adipocytes with cell membrane-
permeable cAMP analogs, we observed a 1.5-fold increase in RND3
mRNA. This effect likely occurred through the PKA pathway since the
cAMP analog 8CPT-cAMP, which targets PKA as well as the alternative
Epac pathway, showed no additional effect compared to the PKA-
specific analog 6 MB-cAMP (Fig. 7A).
We next assayed lipolysis measured as glycerol release following
RND3 knockdown in primary human adipocytes. Knockdown decreased
lipolysis up to 35% depending on the cellular condition (Fig. 7B).
Whereas knockdown reduced basal lipolysis only slightly, the knock-
down potently attenuated cAMP-stimulated lipolysis. Conversely, treat-
ment with ROCK inhibitor increased lipolysis about 2-fold, consistent
with a positive effect of ROCK on insulin-mediated suppression of lipol-
ysis. Surprisingly, however, the ROCK inhibitor attenuated the cAMP-
stimulated lipolysis (Fig. 7B), possibly due to a saturation effect as
cAMP stimulation already increased lipolysis 50-fold. We further
found that RND3 knockdown inhibited lipolysis induced by isoprotere-
nol, a catecholamine-mimicking beta3-adrenergic receptor agonist that
activates cAMP/PKA signaling in adipocytes. When treated with ROCK
inhibitor, to “rescue” the loss of ROCK inhibition upon RND3 knock-
down, the adipocytes showed increased basal as well as isoproterenol-
stimulated lipolysis as expected (Fig. 7B).
PKA-mediated phosphorylation of ser650 on HSL (typically referred
to as ser660 which is the equivalent residue in rat) is an important
mechanism for inducing adipocyte lipolysis in vivo, through a crosstalk
with AMPK signalingwhich also regulates ATGL activity [14].We there-
fore measured the effect of RND3 knockdown and ROCK inhibitor on
pHSLser650 by Western blotting, as well as on total HSL and ATGL
levels. The Western blots confirmed a reduction in RND3 protein
(Fig. 7C). Both knockdown and ROCK inhibitor reduced ATGL protein
levels. Further, while total HSL levels were unchanged, levels of
pHSLser650 were reduced (Fig. 7C), indicating that RND3 and RhoA/
ROCK are required for PKA-mediated activation of lipolysis in adipo-
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Fig. 5. RND3 knockdown affects genes involved in lipid metabolism and inflammation in primary human adipocyte cultures. Cultures from 6 people were transfected with control non-
targeting siRNA (siNT) or siRNA targeting RND3 from day 6 to 8 after induction of adipocyte differentiation (48 h). Global gene expression was measured by RNA sequencing A.
Principal component analysis (PCA) depicting the effect of RND3 knockdown on global gene expression (adjusted for effects of the individuals). B. Volcano plot depicting fold changes
for differentially expressed genes comparing non-targeting and RND3 siRNA. C. Heatmap showing relative expression of the 50 most up-regulated and 50 most down-regulated genes
with RND3 knockdown (for genes with P.adjust b0.1 in the RNA-seq dataset). 0 represents an expression of 0, and 1 represents the maximum observed expression for that gene across
all samples, to which all other samples for the same row are compared. D. KEGG pathways with a significant enrichment of differentially expressed genes with RND3 knockdown (for
genes with false discovery rate (FDR) b 0.1). All pathways passed FDR b 0.05 for enrichment. E. Relative expression of the genes in the enriched KEGG pathways for up-regulated genes
with RND3 knockdown. Data are presented as mean ± SD. Reg., Regulation; siNT, small interfering non-targeting RNA.
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Fig. 6. Effect of ROCK inhibition on metabolic pathways in DFAT cells and expression of ROCK isoforms in tissues from obesity- and insulin resistance-prone mice. A. The mouse DFAT
(dedifferentiated fat) cell line was treated for 4 days with and without ROCK inhibitor (Y-27632, 30 mM), as described previously [43]. Genes with a fold change N2 compared to
control were subjected to KEGG pathway analysis, revealing highly significant fold enrichment of these genes in three categories relative to the count of genes in these pathways
expected by chance. B. Lean and obese (ob/ob) B6 and BTBR mice were fed for 4 or 10 weeks (ab libitum). Adipose tissue (epididymal), liver, hypothalamus, soleus, gastrocnemius and
pancreatic islets were analyzed (n = 5). Data are presented as mean ± SD. P-values were calculated by one-way ANOVA and Tukey's posthoc test. B6, C57BL/6 inbred mouse strain;
BTBR, Black and Tan BRachyury mouse strain; Ob, obese; Ob/ob, obese leptin-deficient. * p b .05; ** p b .01; *** p b .001.
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drome through inhibition of ROCK proteins, which alleviates an inhibi-
tory effect on adipocyte lipolysis (Fig. 7D).
4. Discussion
In the present study we explored the potential roles of the Rho
GTPase RND3 in obesity-related adipose tissue function.We revealed el-
evated RND3 mRNA expression in obesity, and novel correlations be-
tween adipose RND3 mRNA expression and features of insulin
resistance syndrome in humans, including positive correlations with
HOMA2-IR, TAG/HDL ratio and adipocyte size. These correlations were
partly independent of BMI. Our experimental data further indicate
that altered RND3 expression causally regulates adipose tissue function,
with a particular link to pathways involved in inflammatory responses
and adipocyte lipid handling.
We found that RND3 knockdown consistently reduced adipocyte li-
polysis, in the basal state as well as upon stimulation of lipolysis bycAMP or beta-adrenergic receptor agonist (isoproterenol). Conversely,
pharmacologic inhibition of ROCK overall increased lipolysis, consistent
with a lipolytic effect of RND3-mediated ROCK inhibition which may
impair insulin signaling. These data are in line with our observed
association between RND3 mRNA and insulin resistance, as well as
with previous studies implicating reduced skeletal muscle ROCK1
activity in systemic insulin resistance [23,45]. Further consistent with
our data linking RND3 to impaired insulin signaling and lipolysis,
selective inhibition of ROCK2 in 3T3-L1 adipocytes was recently
shown to impair adipogenesis [42]. Furthermore, this ROCK2 inhibitor
was found to promote lipid accumulation in adipose tissue macro-
phages (ATMs) and thereby favor macrophage polarization towards
the pro-inflammatory M1 rather than the anti-inflammatory M2 type
[46]. Thus, increased adipocyte lipolysis due to increased RND3 activity
might promote pro-inflammatory lipid accumulation in ATMs. This
effect may be further exacerbated by increased RND3mRNA expression
upon pro-inflammatory stimuli (LPS, TNFα) as we observed in primary
human hASCs. These stimuli upregulate lipolytic genes partially via
Fig. 7. Knockdown of RND3 reduces cAMP- and isoproterenol-stimulated lipolysis. Primary human adipose stromal cells or SGBS cells were differentiated in vitro. A. Human adipose
stromal cells differentiated towards adipocytes for 3 days were treated with cAMP analogs (6 MB-cAMP or 8CPT-cAMP) for 24 h. RND3 mRNA was measured by qPCR (calculated
relative to IPO8). Data are presented as mean ± SD. B. hASCs were transfected at day 8 of differentiation with siRNAs targeting RND3. On the day of analysis, the cells were incubated
for 3 h in DMEM-F:12 medium supplemented with 20 g/L of BSA and 1 mM of dibutyryl cAMP (dcAMP) or 1 μM norepinephrine, with and without 10 μM ROCK inhibitor (ROCKi).
Results are based on three individual experiments with each condition performed at least in triplicates. C. Differentiated SGBS cells (day 15) were transfected with control or RND3
siRNA for 72 h, and treated with 10 μM ROCK inhibitor for 24 h. Protein samples were analyzed by SDS-PAGE and immunoblotting (20 μg protein for the RND3 blot and 35 μg protein
for the p-ser650 HSL and ATGL blots). Membranes were blocked by 5% BSA for 1 h at room temperature, followed by repeated washing in 1xTBS tween, overnight exposure to the
primary antibody in buffer with 5% BSA at 4°C, repeated washing, exposure to the secondary antibody (anti-rabbit 1:10000 or anti-mouse 1:5000) in 5% BSA for 30 min at room
temperature, repeated washing, and detection by ChemiDOC MP imager (BioRad). D. Proposed mechanistic model for the contribution of RND3 to insulin resistance syndrome,
mediated via inhibition of ROCK signaling, supported expression and activation of rate-limiting lipolytic enzymes HSL and ATGL, and resultant augmentation of lipolysis in adipocytes.
cAMP, cyclic adenosine monophosphate; ROCKi, ROCK inhibitor; siRNA, small interfering RNA. * p b .05; ** p b .01.
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RND3 may therefore be part of a vicious cycle of insulin resistance,
inflammation and adipocyte lipolysis that manifests upon chronic
overfeeding.
The comparison of ROCK expression across tissues points to an im-
portant role for both ROCK isoforms in adipose tissue, which showed in-
creased expression inmousemodels of diet-induced obesity and insulin
resistance. Despite higher expression ofRock2 in legmuscle,we only ob-
served altered Rock2 expression in adipose tissue. Furthermore, the
change in Rock1 expression was opposite in adipose tissue compared
to other metabolic tissues. These data support specific roles for the
ROCK proteins in adipocytes. The increase in ROCK expression specifi-
cally in adipose tissue might reflect a transcriptional feedback mecha-
nism that attenuates the loss of ROCK activity upon increasing insulin
resistance. It should be noted, however, that when knocking out the
ROCK1 isoform selectively in adipocytes, Lee et al. found enhanced sig-
naling through the insulin receptor, although the isoform-specific loss
of ROCK1 only modestly affected whole-body insulin sensitivity [41].
It could be that the increased adipocyte lipolysis observed upon RND3
knockdown and ROCK inhibition involved enhanced insulin signaling,
given the co-expression we observed upon RND3 knockdown of genes
involved in lipolysis and insulin signaling, and since prolonged insulin
exposure has been found to enhance cAMP- and isoproterenol-
stimulated lipolysis [50]. However, the precise mechanisms that medi-
ate the effect of RND3 on HSL/ATGL levels and adipocyte lipolysis need
to be further delineated. The RNA-sequencing data suggest that AMPK
signaling, which is elevated in conditions associated with lipolysis
such as fasting, could also be involved. Further, we cannot rule out ef-
fects of RND3 also independent of ROCK signaling, as in the regulation
of cell cycle progression [22].
Importantly, whole-body insulin sensitivity can improve upon
partial inhibition of lipolysis [6,16], supporting that RND3-
mediated stimulation of lipolysis may be a causal mechanism that
leads to insulin resistance, and making RND3 a potential therapeutic
target to prevent the development of insulin resistance, inflamma-
tion and associated metabolic diseases. We further found a positive
correlation between RND3 mRNA and adipocyte size. Adipocyte hy-
pertrophy is a hallmark of adipose tissue inflammation in patientswith insulin resistance independent of obesity [4,51]. Moreover, ad-
ipocyte hypertrophy may cause adipose and systemic insulin resis-
tance also in the absence of adipose inflammation [52]. Despite
their increased lipid accumulation, hypertrophic adipocytes are
characterized by elevated rates of lipolysis, which may contribute
to increased circulating FFA concentrations, ectopic lipid accumula-
tion, and systemic insulin resistance [9,53].
The inverse relationship we found between RND3 in adipocytes and
a PPARγ-related gene signature suggests a mechanism by which RND3
promotes insulin resistance, since adipocyte PPARγ activity promotes
whole-body insulin sensitivity, epitomized by pharmacologic treatment
with PPARγ-specific ligands such as rosiglitazone. Rosiglitazone-
mediated PPARγ activation promotes glyceroneogenesis in subcutane-
ous adipocytes to favor TAG synthesis over lipolysis [54], in a subtle
balance between lipid storage and release with implications for
systemic insulin resistance and metabolic disease risk [9]. Accordingly,
we previously demonstrated that adipocytes of people who are suscep-
tible to insulin resistance and T2D, as a result of carrying a T2D risk allele
in the PPARG locus, have decreased glyceroneogenesis (pyruvate
incorporation into TAG) and increased lipolysis (FFA release) [55].
Consistently, dose-dependent restoration of insulin resistance with
rosiglitazone involves decreased levels of cAMP and inhibition of lipoly-
sis [56]. It should be noted that elevated circulating FFA levels in T2D
may also result from de novo lipogenesis and impaired lipid handling
independent of lipolysis [17].
It is further possible that RND3 at least partly affected adipocyte
lipolysis by modulating actin stress fibers and cell structure, as a pri-
mary function of RND3 is to serve as an endogenous antagonist of
RhoA/ROCK signaling and thereby modulate actin cytoskeleton dy-
namics [21]. Effects of RhoA/ROCK signaling on cytoskeleton dynam-
ics has been implicated in adipocyte function [43]. Another small
GTPase which regulates actin cytoskeleton, membrane receptor traf-
ficking and endocytosis, ADP-ribosylation factor 6 (Arf6), has been
found to modulate lipolysis in response to beta-adrenergic (but not
cAMP) stimulation, which may involve adrenergic receptor traffick-
ing [57]. In line with our findings for RND3 knockdown, Arf6 knock-
down in 3 T3-L1 adipocytes reduced isoproterenol-stimulated
lipolysis. Future studies should explore the possible role of altered
11S.N. Dankel et al. / Metabolism Clinical and Experimental 101 (2019) 153999actin cytoskeleton and receptor trafficking in mediating the RND3-
dependent regulation of lipolysis.
Our study has strengths as well as limitations. A major strength of
our study is the analyses of adipose gene expression and clinical data
in several human cohorts, and experimental and functional assays
performed in primary human adipocyte cultures based on a system-
atic whole-genome screen. On the other hand, the in vivo human ex-
pression data were correlative and do not establish causality, and we
cannot necessarily extrapolate the in vitro data to an organismal
context. For example, although we found a causal effect of RND3 per-
turbation on adipocyte lipolysis in cultured primary human adipo-
cytes, e.g., in the context of cAMP signaling which partly mediates
lipolytic effects of pro-inflammatory stimuli [48,49], these cultures
do not necessarily reflect the context of cellular stress associated
with obesity and insulin resistance in vivo. Thus, our data encourage
future studies that perturb adipocyte Rnd3 in vivo, such as by
adipocyte-specific conditional knockout in a mouse model of diet-
induced obesity and insulin resistance. Finally, although we used
ROCK inhibitor to mimic increased endogenous RND3 activity,
RND3 overexpression in primary human adipocytes could further in-
form on the dynamics of lipolysis regulation at different RND3 levels,
also in the context of adipose tissue stress related to insulin resis-
tance. In primary in vitro differentiated adipocytes, such studies
must be carefully balanced to ensure physiological expression levels
and avoid non-specific toxic effects.
5. Conclusion
In conclusion, we here uncovered a differential expression of adi-
pose RND3 in obesity and insulin resistance, and a causal role for
RND3 in adipocyte lipolysis.Mechanistically, RND3 knockdown reduced
protein levels of both ATGL and ser650-phosphorylated HSL, attenuat-
ing the stimulatory effects of isoproterenol and cAMP signaling on lipol-
ysis. These clinical and experimental data together highlight RND3 as a
novel potential target for therapeutic intervention to improve adipocyte
lipid handling and ameliorate obesity-related insulin resistance.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.metabol.2019.153999.
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